Cough Variant Asthma Clinical Trial
Official title:
The Efficacy of Budesonide/Formoterol in Cough Variant Asthma -- A Multi-center Randomized, Controlled Clinical Trial
Cough variant asthma (CVA), subtype of bronchial asthma, is considered to be one of the most
common causes of chronic cough in different cough guidelines of United States, Europe, China
and other countries. From a multicenter survey in China, over one third of chronic cough is
caused by CVA, which is higher than western countries. CVA differs from classic asthma,
usually manifesting a symptom of only coughing without wheezing or dyspnea and particularly
coughing at night. With less clinical manifestation and medical intervention, CVA patients
are easily be neglected and misdiagnosed, and 30-40% of them will develop to typical asthma
in the next few years. Currently there's no specific therapy recommendation for CVA in GINA.
Although cough guidelines in China recommend that CVA patients should be treated as typical
asthma, no recommendation on details about ICS/LABA dosage and duration. There are only a few
sporadic CVA therapy researches with small sample size. Two studiesfound that CVA patients
can't get cough symptom relief even after treating by low dose of ICS/LABA for 3 months. Some
patients' cough symptom relapses during the 24-week follow-up phase after treating by
ICS/LABA for 3 months. Overall, the best treatment of CVA is not yet clear.
GINA 2018 emphasize that asthma need long-term management. Euro-SMART study found that
budesonide/formoterol 2 inhalation twice daily plus as needed can reduce daytime asthma
symptoms and night-time awakenings, as well as reduce exacerbation risk more than 1
inhalation twice daily. Based on the above reasons, We assume that increase the dosage of
ICS/LABA can decrease relapse rate in CVA patients with severe cough. This multi-center,
randomized, controlled clinical trial can help to clarify the best dosage of
budesonide/formoterol of CVA in China.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03319043 -
Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03105843 -
Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Mannitol
|
Phase 4 | |
| Recruiting |
NCT05459805 -
Multicenter Clinical Study on the Optimal Treatment Protocol and Outcome of Cough Variant Asthma With Chinese and Western Medicine
|
N/A | |
| Unknown status |
NCT02002754 -
The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma
|
Phase 4 | |
| Not yet recruiting |
NCT01170429 -
Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA)
|
Phase 4 | |
| Completed |
NCT04203472 -
Optimal Type of Inhaler in Cough Variant- or Cough Predominant Asthma
|
N/A | |
| Recruiting |
NCT03169699 -
Acoustic Analytic Apps for Smart Telehealth Screening - Creating a Big Data
|
N/A | |
| Completed |
NCT01064245 -
Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests
|
N/A | |
| Completed |
NCT03363698 -
MCT and Capsaicin Provocation Challenge in Diagnosis of Chronic Cough
|
||
| Completed |
NCT03573284 -
Validity of Fractional Exhaled Nitric Oxide and Impulse Oscillometry in Patients With Cough Variant Asthma
|
N/A | |
| Completed |
NCT00660114 -
Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Children Outpatients
|
N/A |